Therapy Areas: Devices
Tubulis Raises EUR 60m in Series B Financing
4 May 2022 - - Germany-based Tubulis has completed a EUR 60m (USD 63m) series B financing led by Andera Partners with participation from new investors Evotec and Fund+, the company said.

All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds, Occident and Seventure Partners.

The new capital will be used to advance Tubulis' proprietary pipeline of uniquely assembled antibody drug conjugates, towards clinical evaluation as well as introduce programs addressing a range of solid tumor indications.

The proceeds will enable the company to deliver the true therapeutic potential of ADCs through further innovation of novel payload classes and identification of new cancer targets.

In conjunction with the round, Sofia Ioannidou, PhD, Partner at Andera Partners, Thomas Hanke, PhD, EVP, Head of Academic Partnerships at Evotec as well as Jan Van den Bossche, Partner at Fund+ will join Tubulis' board of directors consisting of Sebastian Pünzeler, PhD, Principal at coparion, Dominik Schumacher, PhD, CEO of Tubulis and Christian Grøndahl, MD, DVM, PhD, MBA, the chairman of the board.

In addition, Valentin Piëch, PhD, Partner at BioMedPartners will take over the board seat from Michael Wacker, PhD, General Partner at BioMedPartners. Biographies for all board members can be found on the website using the following link.

Tubulis' capability of creating a pipeline of antibody-drug conjugates is based on a diverse range of targeting molecules, novel payloads and proprietary conjugation technologies.

They enable the discovery of truly innovative ADCs that go beyond traditional payload classes and can increase antibody conjugation options via novel chemical groups leading to stable, high drug-to-antibody ratios.

Tubulis said it has developed superior Topoisomerase-I linker-payloads with significantly improved pharmacokinetic properties and unique conjugation chemistry enabling access to a novel payload class that has been chemically challenging for conjugation in the past.

The company's lead tumor-targeting assets build upon this technological breadth and are currently in preclinical development addressing several high unmet medical need indications.

Tubulis' pipeline also includes a program for hematological tumors, which is on the path towards IND-readiness.

Tubulis remains focused on pairing novel payloads with disease-specific targets to tackle the five deadliest cancer indications globally.

Baker McKenzie (Julia Braun) served as counsel for new series B investors and CMS (Stefan-Ulrich Müller) for Tubulis.

Created over 20 years ago, Andera Partners is in private company investments in France and internationally.

Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 90 professionals, of which 56 are investment professionals. It is structured as a partnership and managed by a board of 10 partners.

Bayern Kapital GmbH based in Landshut was founded on the initiative of the Bavarian government in 1995. It is a wholly-owned subsidiary of the Bavarian LfA Förderbank.

As the venture capital organisation of the Land of Bavaria, Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria.

Based in Basel, Switzerland, BioMedPartners is an independent European venture capital firm that acts as lead- or co-lead investor providing private equity to early- to mid-stage life sciences companies.

Coparion provides venture capital to accelerate momentum and growth. With a current active fund of EUR 275m coparion has the means to do so. coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations.

Evotec is a life science company.

Fund+ is a Belgian venture capital firm that invests in innovative European Life Sciences companies developing drugs, medical devices and diagnostics, with a strong focus on patient-centric approaches and major unmet medical needs.

High-Tech Gründerfonds is a seed investor that finances high-potential, tech-driven start-ups.

Occident is an international venture capital investor with offices in Zug and Munich, is owner-managed and invests own wealth.

Seventure Partners is a long term equity investor.